BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15625369)

  • 1. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
    J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
    Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
    Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Lecomte J; Berghmans T; Thiriaux J; Florin MC; Efremidis A; Alexopoulos CG; Recloux P; Ninane V; Mommen P; Paesmans M; Klastersky J;
    Ann Oncol; 2002 Jun; 13(6):874-82. PubMed ID: 12123332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Ferry D; Billingham L; Jarrett H; Dunlop D; Woll PJ; Nicolson M; Shah R; Thompson J; Spicer J; Muthukumar D; Skailes G; Leonard P; Chetiyawardana AD; Wells P; Lewanski C; Crosse B; Hill M; Gaunt P; O'Byrne K
    Eur J Cancer; 2017 Sep; 83():302-312. PubMed ID: 28780466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
    Tonato M; Crinó L; Mosconi AM
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-31-S8-35. PubMed ID: 9207314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
    Rosell R; Tonato M; Sandler A
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
    Grigorescu A; Ciuleanu T; Firoiu E; Muresan DR; Teodorescu G; Basson BR
    Lung Cancer; 2007 Aug; 57(2):168-74. PubMed ID: 17467848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
    Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
    Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
    J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
    Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
    J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
    Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
    J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.